Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Xbrane Biopharma

9.75 SEK

+7.18 %

Less than 1K followers

XBRANE

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
+7.18 %
-9.76 %
-71.14 %
-69.78 %
-51.51 %
-56.88 %
-99.02 %
-99.02 %
-97.96 %

Xbrane Biopharma is a biotechnology company focused on the development of biosimilars and biologics. The company is researching new therapies that can improve patient outcomes and quality of life. The products are used in the treatment of prostate cancer and endometriosis, as well as rare and serious eye diseases. Xbrane Biopharma was founded in 2008 and is headquartered in Solna, Sweden.

Read more
Market cap
200.82M SEK
Turnover
967.08K SEK
Revenue
198.72M
EBIT %
-109.66 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
20/2
2026

Annual report '25

5/5
2026

Interim report Q1'26

5/5
2026

General meeting '26

All
Webcasts
Press releases
ShowingAll content types
Regulatory press release11/25/2025, 1:57 PM

Finansinspektionen: Flaggningsmeddelande i Xbrane Biopharma AB

Xbrane Biopharma
Regulatory press release11/24/2025, 4:30 PM

Xbrane Biopharma beslutar om emission av 420 517 teckningsoptioner till Fenja Capital II A/S inom ramen för villkorad finansieringslösning

Xbrane Biopharma
Regulatory press release11/24/2025, 4:30 PM

Xbrane Biopharma resolves to issue 420,517 warrants to Fenja Capital II A/S under the conditional financing solution

Xbrane Biopharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release11/19/2025, 7:00 AM

XBRANE UPPDATERAR TIDPLAN FÖR ÅTERINSÄNDNING AV BLA FÖR SIN RANIBIZUMAB-BIOSIMILAR TILL FDA

Xbrane Biopharma
Regulatory press release11/19/2025, 7:00 AM

XBRANE UPDATES ON TIMING FOR RESUBMISSION OF THE BLA FOR ITS RANIBIZUMAB BIOSIMILAR CANDIDATE TO FDA

Xbrane Biopharma
Regulatory press release11/5/2025, 9:51 AM

Finansinspektionen: Flaggningsmeddelande i Xbrane Biopharma AB

Xbrane Biopharma
Press release11/4/2025, 12:50 PM

Redeye: Xbrane Biopharma (Q3 update) - Headwinds have continued

Xbrane Biopharma
Press release11/4/2025, 7:00 AM

Första patienten inkluderad i den pivotala kliniska studien för Xdivane

Xbrane Biopharma
Press release11/4/2025, 7:00 AM

First patient included in Xdivane pivotal clinical trial

Xbrane Biopharma
Regulatory press release11/3/2025, 7:35 AM

ANTALET AKTIER OCH RÖSTER I XBRANE HAR FÖRÄNDRATS TILL FÖLJD AV TIDIGARE OFFENTLIGGJORD OMVÄND SPLIT 1:125.

Xbrane Biopharma
Regulatory press release11/3/2025, 7:35 AM

THE NUMBER OF SHARES AND VOTES IN XBRANE HAS CHANGED AS A RESULT OF THE PREVIOUSLY ANNOUNCED REVERSE SPLIT OF 1:125.

Xbrane Biopharma
Press release10/28/2025, 8:00 PM

Xbrane publishes answers to questions received in recent days.

Xbrane Biopharma
Press release10/28/2025, 8:00 PM

Xbrane publicerar svar på frågor som inkommit senaste dagarna.

Xbrane Biopharma
Press release10/28/2025, 8:00 PM

Siavash Bashiri säljer aktier för att betala av lån som togs i samband med emission under 2024 som nu förfaller till betalning, men kvarstår som dedikerad och långsiktig anställd och aktieägare

Xbrane Biopharma
Press release10/28/2025, 8:00 PM

Siavash Bashiri sells shares to repay loan taken in connection with the 2024 rights issue, but remains a dedicated and long-term employee and shareholder

Xbrane Biopharma
Xbrane Biopharma, Webcast, Q3'25
Webcast10/24/2025, 7:00 AM

Xbrane Biopharma, Webcast, Q3'25

Xbrane Biopharma
Regulatory press release10/24/2025, 6:00 AM

Xbrane Biopharma publicerar Delårsrapport januari-September 2025

Xbrane Biopharma
Regulatory press release10/24/2025, 6:00 AM

Xbrane Biopharma releases Interim Report for January-September 2025

Xbrane Biopharma
Regulatory press release10/20/2025, 6:00 AM

XBRANE BIOPHARMA PRESENTERAR VALBEREDNINGEN

Xbrane Biopharma
Regulatory press release10/20/2025, 6:00 AM

XBRANE BIOPHARMA PRESENTS THE NOMINATION COMMITTEE

Xbrane Biopharma
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.